Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2

The SARS-CoV-2 outbreak, began in late 2019, has caused a worldwide pandemic and shows no signs of slowing. Glucocorticoids (GCs), including dexamethasone (DEX), have been widely used as effective anti-inflammatory and immunosuppressant drugs. In this study, seven GCs had no obvious effect on cell v...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yongjing, Hu, Shiling, Wang, Jue, Xue, Zhuoyin, Wang, Cheng, Wang, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744032/
https://www.ncbi.nlm.nih.gov/pubmed/33387788
http://dx.doi.org/10.1016/j.virol.2020.12.001
_version_ 1783624353021165568
author Zhang, Yongjing
Hu, Shiling
Wang, Jue
Xue, Zhuoyin
Wang, Cheng
Wang, Nan
author_facet Zhang, Yongjing
Hu, Shiling
Wang, Jue
Xue, Zhuoyin
Wang, Cheng
Wang, Nan
author_sort Zhang, Yongjing
collection PubMed
description The SARS-CoV-2 outbreak, began in late 2019, has caused a worldwide pandemic and shows no signs of slowing. Glucocorticoids (GCs), including dexamethasone (DEX), have been widely used as effective anti-inflammatory and immunosuppressant drugs. In this study, seven GCs had no obvious effect on cell viability of angiotensin converting enzyme 2 (ACE2) high expressed HEK293T cells when concentrations were under 10 μM. Molecular docking results revealed that DEX occupied with active binding site of ACE2 of SARS-CoV-2 spike protein. Surface plasmon resonance (SPR) results showed that K(D) value between DEX and ACE2 was (9.03 ± 0.78) e−6 M. Cell membrane chromatography (CMC) results uncovered that DEX had a chromatographic retention. DEX was found out to inhibiting the viropexis into ACE2(h) cells using SARS-CoV-2 spike pseudotyped virus. Therefore, DEX inhibits the entrance of SARS-CoV-2 spike pseudotyped virus into cell by binding to ACE2.
format Online
Article
Text
id pubmed-7744032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-77440322020-12-17 Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2 Zhang, Yongjing Hu, Shiling Wang, Jue Xue, Zhuoyin Wang, Cheng Wang, Nan Virology Article The SARS-CoV-2 outbreak, began in late 2019, has caused a worldwide pandemic and shows no signs of slowing. Glucocorticoids (GCs), including dexamethasone (DEX), have been widely used as effective anti-inflammatory and immunosuppressant drugs. In this study, seven GCs had no obvious effect on cell viability of angiotensin converting enzyme 2 (ACE2) high expressed HEK293T cells when concentrations were under 10 μM. Molecular docking results revealed that DEX occupied with active binding site of ACE2 of SARS-CoV-2 spike protein. Surface plasmon resonance (SPR) results showed that K(D) value between DEX and ACE2 was (9.03 ± 0.78) e−6 M. Cell membrane chromatography (CMC) results uncovered that DEX had a chromatographic retention. DEX was found out to inhibiting the viropexis into ACE2(h) cells using SARS-CoV-2 spike pseudotyped virus. Therefore, DEX inhibits the entrance of SARS-CoV-2 spike pseudotyped virus into cell by binding to ACE2. Elsevier Inc. 2021-02 2020-12-16 /pmc/articles/PMC7744032/ /pubmed/33387788 http://dx.doi.org/10.1016/j.virol.2020.12.001 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zhang, Yongjing
Hu, Shiling
Wang, Jue
Xue, Zhuoyin
Wang, Cheng
Wang, Nan
Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
title Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
title_full Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
title_fullStr Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
title_full_unstemmed Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
title_short Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
title_sort dexamethasone inhibits sars-cov-2 spike pseudotyped virus viropexis by binding to ace2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744032/
https://www.ncbi.nlm.nih.gov/pubmed/33387788
http://dx.doi.org/10.1016/j.virol.2020.12.001
work_keys_str_mv AT zhangyongjing dexamethasoneinhibitssarscov2spikepseudotypedvirusviropexisbybindingtoace2
AT hushiling dexamethasoneinhibitssarscov2spikepseudotypedvirusviropexisbybindingtoace2
AT wangjue dexamethasoneinhibitssarscov2spikepseudotypedvirusviropexisbybindingtoace2
AT xuezhuoyin dexamethasoneinhibitssarscov2spikepseudotypedvirusviropexisbybindingtoace2
AT wangcheng dexamethasoneinhibitssarscov2spikepseudotypedvirusviropexisbybindingtoace2
AT wangnan dexamethasoneinhibitssarscov2spikepseudotypedvirusviropexisbybindingtoace2

Ejemplares similares